Huifeng Yun

5.1k total citations
128 papers, 3.8k citations indexed

About

Huifeng Yun is a scholar working on Rheumatology, Epidemiology and Surgery. According to data from OpenAlex, Huifeng Yun has authored 128 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Rheumatology, 33 papers in Epidemiology and 23 papers in Surgery. Recurrent topics in Huifeng Yun's work include Rheumatoid Arthritis Research and Therapies (50 papers), Systemic Lupus Erythematosus Research (20 papers) and Herpesvirus Infections and Treatments (17 papers). Huifeng Yun is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (50 papers), Systemic Lupus Erythematosus Research (20 papers) and Herpesvirus Infections and Treatments (17 papers). Huifeng Yun collaborates with scholars based in United States, Canada and Germany. Huifeng Yun's co-authors include Jeffrey R. Curtis, Fenglong Xie, Lang Chen, Kenneth G. Saag, Elizabeth Delzell, Kevin Winthrop, Meredith L. Kilgore, Sasha Bernatsky, Emily B. Levitan and James D. Lewis and has published in prestigious journals such as Blood, Annals of Internal Medicine and Gastroenterology.

In The Last Decade

Huifeng Yun

119 papers receiving 3.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Huifeng Yun United States	35	1.5k	857	790	577	538	128	3.8k
Yoon‐Kyoung Sung South Korea	30	1.6k 1.0×	448 0.5×	425 0.5×	288 0.5×	609 1.1×	221	3.3k
Nivedita M. Patkar United States	22	1.1k 0.7×	550 0.6×	484 0.6×	1.0k 1.7×	484 0.9×	29	2.9k
Carter Thorne Canada	36	2.9k 1.9×	541 0.6×	534 0.7×	1.1k 1.9×	963 1.8×	172	4.5k
Liron Caplan United States	36	2.7k 1.8×	250 0.3×	612 0.8×	797 1.4×	749 1.4×	100	4.5k
Marissa Lassere Australia	38	4.2k 2.8×	1.1k 1.3×	232 0.3×	1.2k 2.1×	833 1.5×	122	5.9k
Fenglong Xie United States	38	2.1k 1.3×	483 0.6×	1.3k 1.6×	1.0k 1.8×	882 1.6×	140	4.3k
Sindhu R. Johnson Canada	44	1.9k 1.2×	712 0.8×	667 0.8×	478 0.8×	1.2k 2.3×	156	5.5k
Kath Watson United Kingdom	37	3.6k 2.4×	503 0.6×	583 0.7×	1.4k 2.5×	1.6k 3.0×	79	5.8k
Wietske Kievit Netherlands	38	1.7k 1.1×	498 0.6×	499 0.6×	640 1.1×	1.1k 2.1×	171	4.1k
Alfonso López‐Soto Spain	26	1.0k 0.7×	321 0.4×	235 0.3×	364 0.6×	344 0.6×	83	2.6k

Countries citing papers authored by Huifeng Yun

Since Specialization

Citations

This map shows the geographic impact of Huifeng Yun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huifeng Yun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huifeng Yun more than expected).

Fields of papers citing papers by Huifeng Yun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huifeng Yun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huifeng Yun. The network helps show where Huifeng Yun may publish in the future.

Co-authorship network of co-authors of Huifeng Yun

This figure shows the co-authorship network connecting the top 25 collaborators of Huifeng Yun. A scholar is included among the top collaborators of Huifeng Yun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huifeng Yun. Huifeng Yun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rayens, Emily, Lina S. Sy, Lei Qian, et al.. (2025). Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study. Annals of the Rheumatic Diseases. 84(6). 960–969. 1 indexed citations

Liu, Ye, Tarun Arora, Jingyi Zhang, et al.. (2025). Socioeconomic vulnerability and osteoporosis treatment disparities during COVID-19 lockdown among U.S. medicare enrollees who initiated romosozumab. Osteoporosis International. 36(12). 2555–2566.

Rayens, Emily, Lina S. Sy, Lei Qian, et al.. (2025). Adjuvanted Recombinant Zoster Vaccine is Effective Against Herpes Zoster Ophthalmicus, and is Associated With Lower Risk of Acute Myocardial Infarction and Stroke in Adults Aged ≥50 Years. Clinical Infectious Diseases. 81(5). e441–e445.

Constenla, Dagna, et al.. (2025). Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases. The Journal of Infectious Diseases. 232(6). e931–e940. 1 indexed citations

Yi, Hwang, Dong Hwa Kang, Sei Jin Park, et al.. (2025). Computational Fluid Dynamics (CFD) simulations of indoor aerosol dispersion and spatial COVID-19 infection risk across various air-circulation regimes. Architectural Science Review. 1–30.

Zhang, Chengchen, Haeyoung Lee, Driss Oraichi, et al.. (2024). Risk of incident gout following exposure to recombinant zoster vaccine in US adults aged ≥65 years. Seminars in Arthritis and Rheumatism. 68. 152515–152515.

Constenla, Dagna, et al.. (2024). P986 Effectiveness of the adjuvanted recombinant zoster vaccine (RZV) in preventing herpes zoster (HZ) among patients ≥50 years of age with Inflammatory Bowel Disease in the United States: A retrospective real-world database analysis from 2018 to 2021. Journal of Crohn s and Colitis. 18(Supplement_1). i1779–i1780.

Mudano, Amy S., Fenglong Xie, Jingyi Zhang, et al.. (2024). Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care & Research. 76(10). 1361–1370. 2 indexed citations

Yun, Huifeng, et al.. (2024). Epidural steroid injections and fracture incidence among older individuals with radiculopathy. Journal of Bone and Mineral Research. 40(2). 176–183. 2 indexed citations

10.

Curtis, Jeffrey R., Huifeng Yun, Lang Chen, et al.. (2023). Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry. Rheumatology and Therapy. 10(4). 1055–1072. 4 indexed citations

11.

Sattui, Sebastian E., Iris Navarro‐Millán, Fenglong Xie, et al.. (2022). Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs – Analysis of a national claims database. Seminars in Arthritis and Rheumatism. 57. 152083–152083. 14 indexed citations

12.

Beaumont, Jennifer L., Elizabeth Davis, Jeffrey R. Curtis, David Cella, & Huifeng Yun. (2021). Meaningful Change Thresholds for Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue and Pain Interference Scores in Patients With Rheumatoid Arthritis. The Journal of Rheumatology. 48(8). 1239–1242. 15 indexed citations

13.

Cohen‐Mekelburg, Shirley, Beth Wallace, Tony Van, et al.. (2021). Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease. JAMA Network Open. 4(3). e210313–e210313. 8 indexed citations

14.

Lewis, James D., Frank I. Scott, Colleen Brensinger, et al.. (2018). Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease. The American Journal of Gastroenterology. 113(3). 405–417. 109 indexed citations

15.

Curtis, Jeffrey R., Fenglong Xie, Shuo Yang, et al.. (2018). Risk for Herpes Zoster in Tofacitinib‐Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids. Arthritis Care & Research. 71(9). 1249–1254. 70 indexed citations

16.

Rosenson, Robert S., Shia T. Kent, Todd M. Brown, et al.. (2015). Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease. Journal of the American College of Cardiology. 65(3). 270–277. 119 indexed citations

17.

Beaumont, Jennifer L., James F. Fries, Jeffrey R. Curtis, David Cella, & Huifeng Yun. (2015). Minimally Important Differences for Patient-Reported Outcomes Measurement Information System (Promis) Fatigue and Pain Interference Scores. Value in Health. 18(3). A165–A166. 5 indexed citations

18.

Curtis, Jeffrey R., Fenglong Xie, Huifeng Yun, et al.. (2015). Risk of Hospitalized Infection Among Rheumatoid Arthritis Patients Concurrently Treated With a Biologic Agent and Denosumab. Arthritis & Rheumatology. 67(6). 1456–1464. 44 indexed citations

19.

Curtis, J. Randall, et al.. (2014). FRI0193 Herpes Zoster Infection across Auto-Immune and Inflammatory Diseases: Implications for Vaccination. Annals of the Rheumatic Diseases. 73. 452–452. 4 indexed citations

20.

Zhang, Jie, Elizabeth Delzell, Hong Zhao, et al.. (2011). Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes. Journal of Bone and Mineral Research. 27(4). 858–864. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact